Analysts Set Evolent Health, Inc. (NYSE:EVH) PT at $43.00

Shares of Evolent Health, Inc. (NYSE:EVH) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $42.70.

EVH has been the topic of several analyst reports. Barclays initiated coverage on Evolent Health in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $39.00 target price on the stock. Canaccord Genuity Group dropped their target price on Evolent Health from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, March 28th. Citigroup began coverage on Evolent Health in a report on Monday. They issued a “buy” rating and a $40.00 price target for the company. JPMorgan Chase & Co. decreased their price target on Evolent Health from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, March 15th. Finally, William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a research note on Tuesday, January 9th.

Evolent Health Stock Performance

EVH stock opened at $29.86 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01. The business has a 50-day moving average price of $31.93 and a 200 day moving average price of $30.26. The company has a market capitalization of $3.45 billion, a P/E ratio of -23.51 and a beta of 1.54. Evolent Health has a 1-year low of $23.33 and a 1-year high of $36.70.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.13. The firm had revenue of $556.06 million during the quarter, compared to the consensus estimate of $541.87 million. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. As a group, equities research analysts forecast that Evolent Health will post 0.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EVH. WoodTrust Financial Corp grew its holdings in Evolent Health by 3.2% in the 1st quarter. WoodTrust Financial Corp now owns 44,200 shares of the technology company’s stock valued at $1,449,000 after buying an additional 1,350 shares in the last quarter. First Dallas Securities Inc. purchased a new position in shares of Evolent Health during the 1st quarter worth $256,000. Hodges Capital Management Inc. grew its holdings in shares of Evolent Health by 78.3% during the 1st quarter. Hodges Capital Management Inc. now owns 474,746 shares of the technology company’s stock worth $15,567,000 after purchasing an additional 208,534 shares during the period. Salem Investment Counselors Inc. grew its position in Evolent Health by 1,223.6% in the 1st quarter. Salem Investment Counselors Inc. now owns 120,121 shares of the technology company’s stock valued at $3,939,000 after acquiring an additional 111,046 shares in the last quarter. Finally, Banque Cantonale Vaudoise acquired a new position in Evolent Health in the 1st quarter valued at about $88,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.